Multifactor (YC F25) | $15,000,000 | (Dec 5, 2025)
Lumia Security | $18,000,000 | (Dec 5, 2025)
imper.ai | $28,000,000 | (Dec 5, 2025)
Certified by Founder
Lodge
Illimis Therapeutics
start up
Korea, Republic Of
- Seoul
- 15/07/2025
- Series B
- $42,000,000
Illimis Therapeutics is a platform-based Korean biotech company developing a chimeric fusion protein platform for neurodegenerative diseases such as Alzheimer’s. Our platform is differentiated by its ability to address the concerns of antibody-induced neuroinflammation and subsequent ARIA (Amyloid-Related Imaging Abnormalities) often observed from existing antibody drugs that utilize FcR-mediated phagocytosis of microglia, by utilizing TAM receptor, a novel phagocytic receptor expressed on the surface of glial cells.
- Industry Biotechnology Research
- Website www.illimistx.com
- LinkedIn https://www.linkedin.com/company/illimis-therapeutics/
IMTC | $12,000,000 | (Dec 5, 2025)
Govstream.ai | $3,600,000 | (Dec 5, 2025)
SPhotonix Inc | $4,500,000 | (Dec 5, 2025)
Unlimited Industries | $12,000,000 | (Dec 5, 2025)
Paradigm Health | $78,000,000 | (Dec 5, 2025)
Guide Labs | $9,000,000 | (Dec 5, 2025)
7AI | $130,000,000 | (Dec 5, 2025)
Ply | $8,500,000 | (Dec 5, 2025)
Find Your Grind | $5,000,000 | (Dec 5, 2025)